论文信息 - Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study. - 字舞流文

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.

F. Bidault | B. Escudier | S. Oudard | F. Joly | N. Houédé | P. Barthélémy | B. Laguerre | L. Geoffrois | Y. Vano | K. Slimane | O. Lucidarme | N. Kelkouli | M. Gross‐Goupil | M. Gross-Goupil